|Articles|October 1, 2019

Can ID Consultations Decrease Candida Bloodstream Infection Mortality?

Investigators assessed 90-day all-cause mortality between patients with Candida bloodstream infections who did and did not receive an infectious disease consultation.

Infectious disease consultations in the hospital setting can improve patient outcomes for a variety of different infections, including Staphylococcus aureus, cryptococcosis, and other multidrug-resistant organisms.

Candida bloodstream infections are serious invasive infections that are associated with high mortality. In a new study a team of investigators set out to examine the relationship between infectious disease consultation and differences in management with mortality for Candida bloodstream infections.

The results of the study were published in The Lancet Infectious Diseases.

The retrospective, single-center cohort study was conducted at Barnes-Jewish Hospital in St. Louis, Missouri, a tertiary referral center. The investigators reviewed medical charts for all patients 18-years and older who were admitted to the hospital with a Candida bloodstream infection between 2002 and 2015.

Investigators assessed 90-day all-cause mortality between patients who did and did not receive an infectious disease consultation by evaluating demographics, comorbidities, predisposing factors, antifungal use, central-line removal, and data from ophthalmological and echocardiographic evaluations.

The study team also reports using Cox proportional hazards model with inverse weighting by propensity score for survival analysis to assess the effect of infectious disease consultation.

In total, 1794 individuals were evaluated for eligibility between January 1, 2002, and December 31, 2015. The investigators analyzed 1691 patients with Candida bloodstream infections, of whom 776 (45.9%) had an infectious disease consultation; the remaining 915 individuals (54.1%) did not have an infectious disease consultation.

The investigators included all 1691 patients in the analysis and observed that 90-day mortality was lower in the group who received infectious disease consultations when compared with the group who did not (29% [222 of out 776 patients ] vs 51% [468 out of 915 patients]; p<0·0001).

“In the model with inverse weighting by the propensity score, infectious disease consultation was associated with a hazard ratio of 0.81 (95% CI [confidence interval] 0.73—0.91; p<0·0001) for mortality,” the investigators wrote.

According to the report, most underlying comorbidities were evenly distributed between the groups, but in the group that received infectious disease consultation, the median duration of antifungal therapy was longer (18 [IQR 14—35] vs 14 [6—20] days; p<0.0001). The same was true for central-line removal (587 [76%] of 776 vs 538 [59%] of 915; p<0.0001), echocardiography use (442 [57%] of 776 vs 305 [33%] of 915; p<0.0001), and ophthalmological examination (412 [53%] of 776 vs 160 [17%] of 915; p<0.0001).

Additionally, it is reported that fewer patients in the infectious disease consultation group were not treated (13 [2%] of 776 vs 128 [14%] of 915; p<0.0001).

Based on these findings, the authors of the report conclude that patients with Candida bloodstream infections who received an infectious disease consultation had lower mortality.

“This finding might be attributable to these individuals receiving a higher number of non-pharmacological, evidence-based interventions and lower amounts of non-treatment,” the authors wrote, further concluding that the data suggest infectious disease consultations should be an integral part of candida bloodstream infection care.


Related to this article

Ebola and the Ongoing Tale of US Failures
In mid-May, as the world was still grappling with an unexpected hantavirus outbreak aboard a tourism vessel, news broke of an Ebola outbreak in the Ituri Province of the Democratic Republic of the Congo spanning at least 3 health zones, including Bunia, Rwampara, and Mongbwalu.
This Week's Top 5 Infectious Disease News Stories: September 12-September 18, 2026
In this week's top infectious disease stories, a Pennsylvania teen became the state's fourth measles death in weeks, the CDC reported a 17% summer surge in rabies exposure calls, new research revisited whether cefepime raises mortality risk, a multihospital review examined ceftriaxone's safety after state alerts, and examining Legionella pneumonia diagnostics.
Measles Update: September 18, 2026
The latest CDC numbers show a 5.37% increase of measles cases from week-to-week. In Pennsylvania, the fourth measles-related death was reported in 2026. Additionally, the CDC has made a change in the way it will report deaths.
CDC Responds to Surge in Rabies Exposures
A "Clinician Outreach" from the Centers for Disease Control and Prevention (CDC) in April anticipated an increase in rabies exposures, and the striking surge in case reports this summer prompted a recent health advisory alert from the federal agency.
New Diagnositics for Legionella Pneumonia May Streamline Care Continuum
Reported cases of Legionnaires’ disease have been on the rise for the past decade, and identifying Legionella bacteria requires specialized testing in the microbiology lab. Here is a clinical overview of Legionella bacteria, including required testing, treatment, and reporting to public health officials.
Ceftriaxone Safety: Separating Signal From Risk
A retrospective multihospital study found that severe adverse events occurred at similarly low rates with ceftriaxone and other IV cephalosporins suggesting there is no evidence to support avoiding ceftriaxone despite recent health department safety alerts.